Literature DB >> 18512029

The significance of Treg cells in defective tumor immunity.

Agata Kosmaczewska1, Lidia Ciszak, Stanisław Potoczek, Irena Frydecka.   

Abstract

Regulatory T cells (Treg) enriched in FoxP3+, glucocorticoid-induced TNF receptor+, and cytotoxic T-lymphocyte-associated antigen-4+ exert a potential to suppress effector T cells in the periphery. These cells exist in markedly higher proportions within tumor-infiltrating lymphocytes, peripheral blood lymphocytes, and/or regional lymph node lymphocytes of patients with cancer and their frequencies are suggested to be strongly related to tumor progression and inversely correlated with the efficacy of treatment. Tumor-specific Treg cells require ligand-specific activation and cell-to-cell contact to exert their suppressive activity on tumor-specific effector cells (CD8+ cytotoxic T lymphocytes and CD4+ Th cells), which includes decreased cytotoxity, proliferation, and Th1 cytokine secrection. Depletion or blockade of Treg cells can enhance immune protection from tumor-associated antigens that are expressed as self antigens. Recent studies revealed that lymphoma T cells might adopt a Treg profile as well. Studies assessing the influence of chemotherapy on Treg cells have also been included in this review.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18512029     DOI: 10.1007/s00005-008-0018-1

Source DB:  PubMed          Journal:  Arch Immunol Ther Exp (Warsz)        ISSN: 0004-069X            Impact factor:   4.291


  26 in total

Review 1.  Metronomic chemotherapy: new rationale for new directions.

Authors:  Eddy Pasquier; Maria Kavallaris; Nicolas André
Journal:  Nat Rev Clin Oncol       Date:  2010-06-08       Impact factor: 66.675

2.  Evaluation of immunological escape mechanisms in a mouse model of colorectal liver metastases.

Authors:  Martin Grimm; Martin Gasser; Marco Bueter; Johanna Strehl; Johann Wang; Ekaterina Nichiporuk; Detlef Meyer; Christoph T Germer; Ana M Waaga-Gasser; Andreas Thalheimer
Journal:  BMC Cancer       Date:  2010-03-07       Impact factor: 4.430

3.  Activation of regulatory T cells instigates functional down-regulation of cytotoxic T lymphocytes in human breast cancer.

Authors:  Chao-Hsu Li; Wen-Hong Kuo; Wen-Chun Chang; Su-Cheng Huang; King-Jen Chang; Bor-Ching Sheu
Journal:  Immunol Res       Date:  2011-10       Impact factor: 2.829

Review 4.  Molecular alterations in glioblastoma: potential targets for immunotherapy.

Authors:  Azizul Haque; Naren L Banik; Swapan K Ray
Journal:  Prog Mol Biol Transl Sci       Date:  2011       Impact factor: 3.622

Review 5.  Metronomic chemotherapy in progressive pediatric malignancies: old drugs in new package.

Authors:  Ankur Bahl; Sameer Bakhshi
Journal:  Indian J Pediatr       Date:  2012-04-28       Impact factor: 1.967

6.  Metronomic Chemotherapy: Seems Prowess to Battle against Cancer in Current Scenario.

Authors:  Prema Muthusamy; Krishnan Vengadaragava Chary; G K Nalini
Journal:  J Clin Diagn Res       Date:  2016-11-01

7.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

8.  Tumor infiltrating lymphocytes but not serum pituitary antibodies are associated with poor clinical outcome after surgery in patients with pituitary adenoma.

Authors:  Isabella Lupi; Luca Manetti; Patrizio Caturegli; Michele Menicagli; Mirco Cosottini; Aldo Iannelli; Giovanni Acerbi; Generoso Bevilacqua; Fausto Bogazzi; Enio Martino
Journal:  J Clin Endocrinol Metab       Date:  2009-10-29       Impact factor: 5.958

9.  Circulating CD4-positive lymphocyte levels as predictor of response to induction chemotherapy in patients with advanced laryngeal cancer.

Authors:  Nicholas A Dewyer; Gregory T Wolf; Emily Light; Francis Worden; Susan Urba; Avraham Eisbruch; Carol R Bradford; Douglas B Chepeha; Mark E Prince; Jeffrey Moyer; Jeremy Taylor
Journal:  Head Neck       Date:  2013-06-14       Impact factor: 3.147

10.  Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model.

Authors:  Debbie Liao; Yunping Luo; Dorothy Markowitz; Rong Xiang; Ralph A Reisfeld
Journal:  PLoS One       Date:  2009-11-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.